An interventional study of walking free online supervised program in Phenylketonurias and Non Alcoholic Fatty Liver, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 9 Years to 12 Years. Per ClinicalTrials.gov, last updated 2024-12-05.
Sponsored by Cairo University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
phenylketonuria (commonly known as PKU) is an inherited disorder that increases the levels of a substance called phenylalanine in the blood. PKU is usually associated with many metabolic complication including non-alcoholic fatty liver
this study will include PKU children sufferers 9n=40) with non-alcoholic fatty liver to be randomly assigned to group I (n=20) that will perform walking program (online supervised free walking that will be applied daily for eight weeks) or group II (N=20) that will act as waitlisted children
191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.
This study's planned enrollment of 40 is above the median of 27 across 122 interventional studies indexed under Phenylketonurias.
Browse Phenylketonurias studies →Cairo University is the lead sponsor of 4,967 studies on the registry; 1,474 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
this Group I will include PKU children sufferers (n=20) with non-alcoholic fatty liver that will perform walking program (online supervised free walking that will be applied daily for eight weeks)
Behavioral: walking free online supervised program
this Group II will include PKU children sufferers (n=20) with non-alcoholic fatty liver that will act a waitlisted children
this Group I will include PKU children sufferers (n=20) with non-alcoholic fatty liver that will perform walking program (online supervised free walking that will be applied daily for eight weeks)
alanine transamianse
it is a serum liver enzyme
Time frame: it will be assessed after eight weeks
aspartate tranaminase
it is a serum liver enzyme
Time frame: it will be assessed after eight weeks
Gamma-glutamyl Transferase
it is a serum liver enzyme
Time frame: it will be assessed after eight weeks
alkaline phosphatase
it is a serum liver enzyme
Time frame: it will be assessed after eight weeks
triglycerides
it will be measured in the serum
Time frame: it will be assessed after eight weeks
body mass index
it will be measured after emptying bladder
Time frame: it will be assessed after eight weeks
Started Sep 2024 (actual). Primary completion is estimated for Jan 2025, 4 months after the start.
Of 33 interventional studies with no phase under Phenylketonurias, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 28. This study's planned 4 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.